Different IVIG glycoforms affect in vitro inhibition of anti-ganglioside antibody-mediated complement deposition

• Published in: PloS one 2014-09, Vol.9 (9), p.e107772-e107772
• Main Authors: Sudo, Makoto, Yamaguchi, Yoshiki, Späth, Peter J, Matsumoto-Morita, Kana, Ong, Benjamin K, Shahrizaila, Nortina, Yuki, Nobuhiro
• Format: Article
• Language: English
• Subjects: Acids; Antibodies; Antibody-dependent cell-mediated cytotoxicity; Autoantibodies; Autoantibodies - immunology; Autoimmune diseases; Biology and Life Sciences; Cell culture; Chromatography; Complement; Complement component C3; Complement System Proteins - immunology; Complement System Proteins - metabolism; Cytotoxicity; Deposition; Gangliosides - antagonists & inhibitors; Gangliosides - immunology; Glycosidases; Glycosylation; Humans; Immunoglobulin G; Immunoglobulin G - immunology; Immunoglobulin G - metabolism; Immunoglobulin G - pharmacology; Immunoglobulin M; Immunoglobulins; Immunoglobulins, Intravenous - immunology; Immunoglobulins, Intravenous - metabolism; Immunoglobulins, Intravenous - pharmacology; In Vitro Techniques; Inflammation; Inhibition; Intravenous administration; Laboratory equipment; Medical treatment; Medicine; Medicine and Health Sciences; Miller-Fisher syndrome; Neuropathy; Polysaccharides - metabolism; Progressive motor neuropathy; Proteins; Streptococcus infections; Studies; Toxicity
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0107772

Intravenous immunoglobulin (IVIG) is the first line treatment for Guillain-Barré syndrome and multifocal motor neuropathy, which are caused by anti-ganglioside antibody-mediated complement-dependent cytotoxicity. IVIG has many potential mechanisms of action, and sialylation of the IgG Fc portion reportedly has an anti-inflammatory effect in antibody-dependent cell-mediated cytotoxicity models. We investigated the effects of different IVIG glycoforms on the inhibition of antibody-mediated complement-dependent cytotoxicity. Deglycosylated, degalactosylated, galactosylated and sialylated IgG were prepared from IVIG following treatment with glycosidases and glycosyltransferases. Sera from patients with Guillain-Barré syndrome, Miller Fisher syndrome and multifocal motor neuropathy associated with anti-ganglioside antibodies were used. Inhibition of complement deposition subsequent to IgG or IgM autoantibody binding to ganglioside, GM1 or GQ1b was assessed on microtiter plates. Sialylated and galactosylated IVIGs more effectively inhibited C3 deposition than original IVIG or enzyme-treated IVIGs (agalactosylated and deglycosylated IVIGs). Therefore, sialylated and galactosylated IVIGs may be more effective than conventional IVIG in the treatment of complement-dependent autoimmune diseases.